$IVA News

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead

Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026

Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?

Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test

Truist Securities Maintains Buy on Inventiva, Raises Price Target to $18

Inventiva (IVA) Q2 2026 Earnings Call Transcript

Canaccord Genuity Maintains Buy on Inventiva, Raises Price Target to $21

Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...

Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript

Inventiva S.A. 2026 Q2 - Results - Earnings Call Presentation

Inventiva Q2 Earnings Call Highlights

Inventiva H1 2026 Earnings Call: Complete Transcript

Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update

Inventiva H1 EPS $(0.29) Misses $(0.20) Estimate, Sales $23.251K Miss $10.000M Estimate

Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14

Inventiva to Present Multiple Abstracts at Paris MASH 2026

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

Inventiva Completes Final 72-Week NATiV3 Patient Visit With 1,419 Patients Enrolled, Topline Results Expected Q4 2026